CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

被引：35
|
作者：
Petrioli, Roberto [1 ]
Licchetta, Antonella [1 ]
Roviello, Giandomenico [1 ]
Pascucci, Alessandra [1 ]
Francini, Edoardo [1 ]
Bargagli, Gianluca [1 ]
Conca, Raffaele [1 ]
Miano, Salvatora Tindara [1 ]
Marzocca, Giuseppe [2 ]
Francini, Guido [1 ]
机构：
[1] Univ Siena, Med Oncol Unit, I-53100 Siena, Italy
[2] Univ Siena, Dept Gen Surg, I-53100 Siena, Italy
来源：
CANCER INVESTIGATION | 2012年 / 30卷 / 01期
关键词：
Capecitabine; CEA; CA19.9; Colorectal cancer; Bevacizumab; Oxaliplatin; Tumor markers; CAPECITABINE PLUS OXALIPLATIN; PHASE-II TRIAL; CARCINOEMBRYONIC ANTIGEN; 1ST-LINE THERAPY; TUMOR-MARKERS; ADENOCARCINOMA; MULTICENTER; SURVIVAL; FOLFOX-4; STAGE;
D O I：
10.3109/07357907.2011.629380
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.
引用
收藏
页码：65 / 71
页数：7
相关论文
共 50 条
  • [21] Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    Hesketh, P. J.
    Sanz-Altamira, P.
    Bushey, J.
    Malek, K.
    Insalaco, L.
    Hesketh, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    Hesketh, Paul J.
    Sanz-Altamira, Pedro
    Bushey, Julie
    Hesketh, Ann M.
    SUPPORTIVE CARE IN CANCER, 2012, 20 (05) : 1043 - 1047
  • [23] Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    Paul J. Hesketh
    Pedro Sanz-Altamira
    Julie Bushey
    Ann M. Hesketh
    Supportive Care in Cancer, 2012, 20 : 1043 - 1047
  • [24] Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens
    Yildiz, Ramazan
    Buyukberber, Suleyman
    Uner, Aytug
    Yamac, Deniz
    Coskun, Ugur
    Kaya, Ali Osman
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    CANCER INVESTIGATION, 2010, 28 (01) : 33 - 37
  • [25] Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer A Randomized Clinical Trial
    Avallone, Antonio
    Piccirillo, Maria C.
    Nasti, Guglielmo
    Rosati, Gerardo
    Carlomagno, Chiara
    Di Gennaro, Elena
    Romano, Carmela
    Tatangelo, Fabiana
    Granata, Vincenza
    Cassata, Antonino
    Silvestro, Lucrezia
    De Stefano, Alfonso
    Aloj, Luigi
    Vicario, Valeria
    Nappi, Anna
    Leone, Alessandra
    Bilancia, Domenico
    Arenare, Laura
    Petrillo, Antonella
    Lastoria, Secondo
    Gallo, Ciro
    Botti, Gerardo
    Delrio, Paolo
    Izzo, Francesco
    Perrone, Franco
    Budillon, Alfredo
    JAMA NETWORK OPEN, 2021, 4 (07) : E2118475
  • [26] Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimen
    Yildiz, R.
    Buyukberber, S.
    Uner, A.
    Yamac, D.
    Coskun, U.
    Kaya, A. O.
    Ozturk, B.
    Yaman, E.
    Benelkli, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 143 - 143
  • [27] Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer:: a real entity?
    Sebagh, M
    Plasse, M
    Lévi, F
    Adam, R
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 331 - 331
  • [28] ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED CHEMOTHERAPY ON LIVER AND SPLEEN SIZE AND THROMBOCYTOPENIA IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Lee, Victor
    Fang, Weijia
    Lam, K. O.
    Choi, Cheukwai
    Ng, Sherry
    Ho, Garrett
    Cheng, Thomas
    Liu, Rico
    Leung, T. W.
    Kwong, D. L. W.
    Zheng, Shusen
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [29] Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy
    Gerger, A.
    Zhang, W.
    Yang, D.
    Bohanes, P. O.
    Ning, Y.
    Winder, T.
    Labonte, M. J.
    Wilson, P. M.
    Benhaim, L.
    El-Khoueiry, R.
    Absenger, G.
    El-Khoueiry, A. B.
    Iqbal, S.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
    Saltz, Leonard B.
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Cassidy, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2013 - 2019
12345